ArticleFrontiers in public health2025
Epidemiological and demographic drivers of ischemic stroke attributed to high fasting plasma glucose from 1990 to 2021: findings from the 2021 global burden of disease study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global burden of cancers attributable to high fasting plasma glucose from 1990 to 2021 and projections until 2031.Diabetology & metabolic syndrome · 2026Article
- The Global Burden and Trends of Premenopausal Breast Cancer by Modifiable Lifestyle Factors From 1990 to 2021 With Prediction Until 2039.Global health, epidemiology and genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to analyze the global, regional, and national burden of Ischemic Stroke (IS) attributed to High Fasting Plasma Glucose (HFPG) from 1990 to 2021, identify risk sources in different areas, and develop a platform to assess the disease burden in 204 countries and regions. Methods: Using data from the 2021 Global Burden of Disease study, we analyzed IS-related deaths and disability-adjusted life years (DALYs) attributed to hyperglycemia from 1990 to 2021. We conducted detailed analyses by region, gender, and age. In different Socio-demographic Index (SDI) regions, we used the Age-Period-Cohort (APC) model to evaluate the impact of age, cohort, and period on Age-Standardized Mortality Rate (ASMR) and decomposition analysis to separate the contributions of population, aging, and epidemiological changes. A visualization platform was built using the Shiny package. Results: In 2021, approximately 18% of all IS-related DALYs and deaths were attributed to HFPG, with an annual percentage change (EAPC) in DALYs of -0.715 (-0.811, -0.620) and deaths of -0.959 (-1.059, -0.859). The primary mortality group was aged 80-84. ASMR, categorized by SDI, showed increases in Low-middle SDI: 0.482 (0.422, 0.542) and Low SDI: 0.287 (0.218, 0.356), particularly in Central Asia, East Asia, North Africa and Middle East, and South Asia. The APC model indicates that age is the primary source of burden in High, High-middle, and Middle SDI regions, with ASMR trends improving over the last 5 years, contrary to trends in Low-middle and Low SDI regions. Decomposition analysis suggests that aging and epidemiological changes in High-middle and High SDI regions outweigh population growth. In contrast, in low, low-middle, and middle SDI regions, the population remains the most significant influence, with the impact of aging increasing. The HFPG-IS platform is accessible at http://116.196.73.86:3838/GBD/HFPG-IS/. Conclusion: There is a significant imbalance in IS health attributed to HFPG globally. In low SDI regions, larger populations face more uneven healthcare distribution, necessitating improvements in healthcare infrastructure, especially in areas like the United Arab Emirates. There should be a focus on metabolic adjustments and attention to high-risk groups, such as those aged 80-84, to reduce health losses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.